2023 Q4 Form 10-Q Financial Statement
#000162828023036375 Filed on November 02, 2023
Income Statement
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
Revenue | $156.0K | $141.0K |
YoY Change | 21.88% | 51.61% |
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $2.725M | $2.939M |
YoY Change | -11.47% | -4.48% |
% of Gross Profit | ||
Research & Development | $7.763M | $8.022M |
YoY Change | 20.51% | 33.5% |
% of Gross Profit | ||
Depreciation & Amortization | $103.0K | $110.0K |
YoY Change | 19.77% | 35.8% |
% of Gross Profit | ||
Operating Expenses | $10.49M | $10.96M |
YoY Change | 10.17% | 20.64% |
Operating Profit | -$10.82M | |
YoY Change | 20.32% | |
Interest Expense | $1.008M | $1.070M |
YoY Change | 36.22% | 133.62% |
% of Operating Profit | ||
Other Income/Expense, Net | -$13.00K | $1.089M |
YoY Change | -71.11% | 158.06% |
Pretax Income | -$9.337M | -$9.730M |
YoY Change | 7.36% | 13.52% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$9.343M | -$9.731M |
YoY Change | 7.35% | 13.53% |
Net Earnings / Revenue | -5989.1% | -6901.42% |
Basic Earnings Per Share | -$0.22 | |
Diluted Earnings Per Share | -$0.21 | -$0.22 |
COMMON SHARES | ||
Basic Shares Outstanding | 44.68M shares | 44.68M shares |
Diluted Shares Outstanding | 44.68M shares |
Balance Sheet
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $47.96M | $52.94M |
YoY Change | -52.17% | -50.62% |
Cash & Equivalents | $21.66M | $15.23M |
Short-Term Investments | $26.31M | $37.71M |
Other Short-Term Assets | $2.301M | $2.300M |
YoY Change | -56.14% | -52.1% |
Inventory | ||
Prepaid Expenses | $2.301M | $2.344M |
Receivables | $288.0K | $198.0K |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $77.41M | $83.91M |
YoY Change | -30.44% | -29.94% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $1.238M | $1.317M |
YoY Change | -2.44% | 1.0% |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $1.279M | $1.387M |
YoY Change | -7.79% | 653.8% |
Total Long-Term Assets | $4.225M | $4.547M |
YoY Change | -13.9% | 17.31% |
TOTAL ASSETS | ||
Total Short-Term Assets | $77.41M | $83.91M |
Total Long-Term Assets | $4.225M | $4.547M |
Total Assets | $81.64M | $88.45M |
YoY Change | -29.74% | -28.45% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $1.966M | $2.179M |
YoY Change | 0.51% | 52.91% |
Accrued Expenses | $7.783M | $6.151M |
YoY Change | 50.34% | 0.21% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $10.44M | $9.018M |
YoY Change | 33.71% | 9.38% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | $1.458M | $1.600M |
YoY Change | -28.53% | -26.4% |
Total Long-Term Liabilities | $1.458M | $1.600M |
YoY Change | -28.53% | -26.4% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $10.44M | $9.018M |
Total Long-Term Liabilities | $1.458M | $1.600M |
Total Liabilities | $11.90M | $10.63M |
YoY Change | 20.82% | 1.98% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$339.5M | -$330.2M |
YoY Change | 13.9% | 13.93% |
Common Stock | $4.000K | $4.000K |
YoY Change | 0.0% | 0.0% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $69.74M | $77.83M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $81.64M | $88.45M |
YoY Change | -29.74% | -28.45% |
Cashflow Statement
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$9.343M | -$9.731M |
YoY Change | 7.35% | 13.53% |
Depreciation, Depletion And Amortization | $103.0K | $110.0K |
YoY Change | 19.77% | 35.8% |
Cash From Operating Activities | -$7.139M | -$7.960M |
YoY Change | -23.97% | 6.33% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $8.000K | $310.0K |
YoY Change | -89.33% | -169.2% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $13.57M | $4.140M |
YoY Change | 91.25% | -26.22% |
Cash From Investing Activities | $13.56M | $3.820M |
YoY Change | 93.18% | -26.01% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 0.000 | 0.000 |
YoY Change | -100.0% | |
NET CHANGE | ||
Cash From Operating Activities | -7.139M | -7.960M |
Cash From Investing Activities | 13.56M | 3.820M |
Cash From Financing Activities | 0.000 | 0.000 |
Net Change In Cash | 6.422M | -4.140M |
YoY Change | -370.97% | 84.16% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$7.139M | -$7.960M |
Capital Expenditures | $8.000K | $310.0K |
Free Cash Flow | -$7.147M | -$8.270M |
YoY Change | -24.49% | 17.5% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2023Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
44677169 | shares |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.69 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001213037 | ||
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
44677000 | shares |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.69 | ||
CY2023Q3 | us-gaap |
Interest Income Operating
InterestIncomeOperating
|
1068000 | usd |
CY2022Q3 | us-gaap |
Interest Income Operating
InterestIncomeOperating
|
458000 | usd |
us-gaap |
Interest Income Operating
InterestIncomeOperating
|
3061000 | usd | |
us-gaap |
Interest Income Operating
InterestIncomeOperating
|
841000 | usd | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.72 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.72 | ||
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
44677000 | shares |
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
44677000 | shares |
CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
43333000 | shares |
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
43333000 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
44677000 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
44677000 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
43291000 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
43291000 | shares | |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1064000 | usd |
CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
319000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11223000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
96503000 | usd |
CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1581000 | usd |
CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-355000 | usd |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11150000 | usd |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
86579000 | usd |
CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
955000 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
-1000 | usd |
CY2022Q1 | us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
6000 | usd |
CY2022Q1 | crdf |
Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
|
139000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10993000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
130102000 | usd |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1055000 | usd |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-234000 | usd |
CY2022Q2 | us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
6000 | usd |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10443000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
120474000 | usd |
CY2022Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1037000 | usd |
CY2022Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
75000 | usd |
CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
203000 | usd |
CY2022Q3 | us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
6000 | usd |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8571000 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
113212000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-32104000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-30007000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
295000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
150000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3600000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3244000 | usd | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
716000 | usd | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-672000 | usd | |
crdf |
Release Of Clinical Trial Funding Commitment For Services Received
ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
|
0 | usd | |
crdf |
Release Of Clinical Trial Funding Commitment For Services Received
ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
|
139000 | usd | |
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
0 | usd | |
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-55000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-573000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
115000 | usd | |
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-3188000 | usd | |
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-4000 | usd | |
crdf |
Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
|
-408000 | usd | |
crdf |
Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
|
-408000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1428000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1325000 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-420000 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-271000 | usd | |
us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
0 | usd | |
us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-34000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-23748000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-24430000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
574000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
931000 | usd | |
us-gaap |
Proceeds From Insurance Settlement Investing Activities
ProceedsFromInsuranceSettlementInvestingActivities
|
0 | usd | |
us-gaap |
Proceeds From Insurance Settlement Investing Activities
ProceedsFromInsuranceSettlementInvestingActivities
|
114000 | usd | |
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
80534000 | usd | |
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
61229000 | usd | |
us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
67491000 | usd | |
us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
80428000 | usd | |
us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
10165000 | usd | |
us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
51145000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
22634000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
31129000 | usd | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | usd | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
75000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
75000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1114000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
6774000 | usd | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
16347000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11943000 | usd |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
15233000 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
18717000 | usd |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | usd | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
255000 | usd | |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
89315000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
20000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
415000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
88920000 | usd |
CY2023Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
81400000 | usd |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9461252 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10934858 | shares | |
CY2023Q3 | us-gaap |
Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
|
37778000 | usd |
CY2023Q3 | crdf |
Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
|
6000 | usd |
CY2023Q3 | crdf |
Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
|
78000 | usd |
CY2023Q3 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
37706000 | usd |
CY2023Q3 | us-gaap |
Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
|
28759000 | usd |
CY2023Q3 | crdf |
Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
|
3000 | usd |
CY2023Q3 | crdf |
Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
|
338000 | usd |
CY2023Q3 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
28424000 | usd |
CY2023Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
66537000 | usd |
CY2023Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
9000 | usd |
CY2023Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
416000 | usd |
CY2023Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
66130000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
|
84299000 | usd |
CY2022Q4 | crdf |
Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
|
19000 | usd |
CY2022Q4 | crdf |
Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
|
394000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
83924000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
|
5016000 | usd |
CY2022Q4 | crdf |
Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
|
1000 | usd |
CY2022Q4 | crdf |
Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
|
21000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
4996000 | usd |
CY2023Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
4981000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
4682000 | usd |
CY2023Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3664000 | usd |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3413000 | usd |
CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1317000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1269000 | usd |
CY2023Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2455000 | usd |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1849000 | usd |
CY2023Q3 | crdf |
Accrued Clinical Trial
AccruedClinicalTrial
|
2878000 | usd |
CY2022Q4 | crdf |
Accrued Clinical Trial
AccruedClinicalTrial
|
2333000 | usd |
CY2023Q3 | crdf |
Accrued Research Agreements
AccruedResearchAgreements
|
591000 | usd |
CY2022Q4 | crdf |
Accrued Research Agreements
AccruedResearchAgreements
|
509000 | usd |
CY2023Q3 | crdf |
Accrued Director Fees
AccruedDirectorFees
|
125000 | usd |
CY2022Q4 | crdf |
Accrued Director Fees
AccruedDirectorFees
|
125000 | usd |
CY2023Q3 | crdf |
Patent License And Other Fees Payable
PatentLicenseAndOtherFeesPayable
|
33000 | usd |
CY2022Q4 | crdf |
Patent License And Other Fees Payable
PatentLicenseAndOtherFeesPayable
|
24000 | usd |
CY2023Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
69000 | usd |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
337000 | usd |
CY2023Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6151000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5177000 | usd |
CY2023Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
955000 | usd |
CY2022Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1037000 | usd |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3600000 | usd | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3244000 | usd | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
4000000 | usd | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
4000000 | usd | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
3150000 | shares |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
5150000 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
3150000 | shares |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
|
600000 | usd |
CY2022Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
4360968 | shares |
CY2022Q4 | crdf |
Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
|
5.33 | |
crdf |
Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
|
P2Y1M6D | ||
CY2023Q3 | crdf |
Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
|
1553020 | shares |
CY2023Q3 | crdf |
Class Of Warrant Or Right Weighted Average Exercise Price Expired During Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod
|
10.54 | |
CY2023Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2807948 | shares |
CY2023Q3 | crdf |
Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
|
2.45 | |
crdf |
Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
|
P2Y2M12D | ||
CY2022Q3 | crdf |
Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made
CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
|
0 | usd |
CY2023Q3 | crdf |
Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made
CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
|
0 | usd |